logo

Progenics Pharmaceuticals Inc (PGNX)



Trade PGNX now with
  Date
  Headline
3/19/2018 8:33:52 AM Progenics Pharma Announces Presentation Of AZEDRA Biochemical Tumor Marker Data
3/8/2018 7:50:03 AM Progenics Pharmaceuticals Q4 Revenue $3.9 Mln, Net Loss Attributable $2.7 Mln Or $0.04 Per Share
12/29/2017 8:32:47 AM Progenics Announces FDA Acceptance Of NDA For AZEDRA In Pheochromocytoma And Paraganglioma
11/2/2017 8:13:15 AM Progenics Pharma Q3 Net Loss $15.4 Mln Or $0.22/shr Vs. Net Income $36.3 Mln Or $0.52/shr Last Year
11/2/2017 7:47:26 AM Progenics Pharma Completes Submission Of NDA For AZEDRA In Pheochromocytoma And Paraganglioma
8/9/2017 7:35:22 AM Progenics Pharma Q2 Revenue $2.8 Mln, Down From $8.5 Mln Last Year
5/4/2017 8:14:21 AM Progenics Pharma Q1 Net Loss Attributable To Progenics $16.4 Mln Or $0.23/Shr Vs Loss $12.7 Mln Or $0.18/Shr Last Year
3/30/2017 6:04:40 AM Progenics: Phase 2b Trial Of Radiotherapeutic Candidate, AZEDRA (iobenguane I 131) Injection, Achieved Primary Endpoint
3/9/2017 7:38:59 AM Progenics Pharmaceuticals Q4 Net Loss Attributable $7.2 Mln Or $0.10 Per Share
2/15/2017 7:44:55 PM Progenics Pharma And Shutterfly To Join S&P SmallCap 600
2/14/2017 7:12:15 AM Progenics Begins Phase 1 Clinical Trial Of PSMA-Targeted Therapeutic Candidate 1095 For Metastatic Prostate Cancer